BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra has signed a contract for a region-wide multimedia archive as a cloud service with SWASH, a British consortium of NHS trusts.

Bayer®, a leader in women’s healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Tuesday, August 11, 2020 at 2:30 p.m. EDT.

Perimeter Medical Imaging AI, Inc. announced the listing of its common shares on the Frankfurt Stock Exchange under the trading symbol “4PC” which can be found at: https://www.boerse-frankfurt.de/equity/perimeter-med-imag-ai.

Mesoblast Limited provided an update on the scheduled meeting of the Oncologic Drugs Advisory Committee of the United States Food and Drug Administration which will review data supporting the Company’s Biologics License Application for approval of RYONCIL™ in the treatment of steroid-refractory acute graft versus host disease in children.

Galderma have announced the start of patient recruitment for the ARCADIA studies, a clinical research program to evaluate an investigational drug in people who have been diagnosed with moderate-to-severe atopic dermatitis.

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the second quarter of 2020.

Generation Bio Co., an innovative genetic medicines company creating a new class of non-viral gene therapy, reported recent business highlights and second quarter financial results.

Centogene N.V. announced a release of CentoMD® 5.8 ̶ the latest update of the Company’s curated mutation database for rare diseases including epidemiologic, phenotypic, and clinical data.

Partnership explores innovative models for real-time identification, patient referral and enrollment of patients with solid tumors with a rare gene fusion